Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.


BRAF(V600E) is the most common mutation in cutaneous melanoma and has become the target of treatment for patients with metastatic melanoma. A number of methods are currently available to determine mutation status. Recently, a monoclonal antibody (VE1) against mutant BRAF(V600E) was generated. Its use permits assessment of the mutant protein expression… (More)
DOI: 10.1097/PAS.0b013e318271249e


6 Figures and Tables

Slides referencing similar topics